Magic mushroom compound could ease bipolar depression in new trial

NCT ID NCT06943573

First seen May 03, 2026 · Last updated May 10, 2026 · Updated 2 times

Summary

This study tests whether a single dose of psilocybin (25 mg), given with therapy, can reduce depression in people with bipolar II disorder who haven't improved with standard treatments. 90 adults aged 19-65 will receive either the full dose or a very low placebo dose, and their symptoms will be tracked for 12 weeks. The goal is to see if this approach is safe and effective for easing depressive episodes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR II DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Psychiatry, University of Ottawa, The Ottawa Hospital

    Ottawa, Ontario, K1H 8L6, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Department of Psychiatry, University of Toronto, University Health Network,

    Toronto, Ontario, M5T 2S8, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Djavad Mowafaghian Centre for Brain Health

    Vancouver, British Columbia, V6T 1Z3, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.